Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MRT-6160 · 1 trial · 1 indication
Frequency of adverse events as assessed by the National Cancer Institute - Common Terminology Criteria for Adverse Events Version 5.0
Frequency of adverse events as assessed by the National Cancer Institute - Common Terminology Criteria for Adverse Events Version 5.0
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose | EXPERIMENTAL | Single Ascending Dose of either: MRT-6160 or matching placebo |
| Multiple Ascending Dose | EXPERIMENTAL | Multiple Ascending Dose of either: MRT-6160 or matching placebo |
| Name | Type | Description |
|---|---|---|
| MRT-6160 | DRUG | Orally administered tablets or capsules of MRT-6160 |
| Placebo | DRUG | Orally administered tablets or capsules of placebo |
Inclusion Criteria: * Healthy, adult, male or females 19-65 years of age * Non smoker who has not used nicotine and tobacco containing products for at least 3 months prior to start of study * Able to swallow oral medications * Understands the study procedures in the informed consent form (ICF) and ...
MRT-6160 is an investigational small molecule being developed by Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE). It is currently in Phase 1 clinical development, having been studied in a first-in-human trial in healthy volunteers. The drug is not approved and remains under clinical investigation.
MRT-6160 is being studied for use in healthy volunteers as part of a first-in-human clinical trial. The study is designed to evaluate the drug's safety, tolerability, and pharmacokinetics in this population. It is not yet approved for any medical condition and is in early-stage clinical development.
MRT-6160 is developed by Monte Rosa Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol GLUE. The company is conducting clinical research on this investigational small molecule, which is currently in Phase 1 development.
MRT-6160 is in Phase 1 clinical development. A first-in-human study in healthy volunteers has been completed. The drug is investigational and has not received FDA approval. It remains in early-stage clinical testing.
MRT-6160 has one completed Phase 1 clinical trial, identified as NCT06597799, titled "First-in-human Study of MRT-6160 in Healthy Subjects." This randomized, double-blind, controlled study enrolled 108 participants in the United States and included healthy volunteers aged 19 years and older.
No alternative names for MRT-6160 have been disclosed. The drug is identified solely by its code name MRT-6160 in clinical trial records and is developed by Monte Rosa Therapeutics. No other designations or brand names are currently associated with this investigational agent.